FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103089294> ?p ?o ?g. }

• W2103089294 endingPage "228" @default.
• W2103089294 startingPage "218" @default.
• W2103089294 abstract "Cyclooxygenases (COXs) are implicated in neurodegenerative processes associated with acute and chronic neurological diseases. Given the potential utility of COX inhibitors in treating these disorders, we examined the nonselective COX inhibitor flurbiprofen, the specific COX-1 inhibitor valeryl salicylate (VS), and the COX-2 inhibitor N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide (NS-398) for their abilities to protect striatal neurons against a quinolinic acid (QA)-induced excitotoxic lesion. Rats were administered COX inhibitors 10 min before a unilateral QA lesion of the striatum, and then tested 2 to 3 weeks later in a battery of motor tasks (bracing, placing, akinesia, and apomorphine-induced rotations). Lesion volume was assessed using immunohistochemical methods 1 month after lesioning. Orally administered flurbiprofen (50 mg) was highly neuroprotective, preserving 84 to 99% of motor performance (ED50 = 8.6-9.7 mg) while reducing lesion volume 75% (ED50 = 3.2 mg). The identities of the COX isoforms associated with QA-induced neurodegeneration were determined using VS and NS-398. Oral VS was ineffective in virtually all indices of functional neuroprotection. In contrast, oral NS-398 was highly effective, preserving approximately 83% of motor performance at2mg(ED50 = 0.1-0.4 mg), and reducing lesion volume 100% (ED50 = 0.4 mg). Similar results were obtained using inhaled flurbiprofen (2 mg), which preserved 88 to 100% of motor performance while reducing striatal lesion size 92%. These results demonstrate that COX-2 inhibition protects neurons from acute, excitotoxic neurodegeneration. Moreover, formulating a nonselective COX inhibitor into an inhalable preparation dramatically improves its potency in treating acute neuronal damage, a situation where the rapidity of drug delivery and onset of action is critical to clinical efficacy." @default.
• W2103089294 created "2016-06-24" @default.
• W2103089294 creator A5005928205 @default.
• W2103089294 creator A5006974397 @default.
• W2103089294 creator A5009703315 @default.
• W2103089294 creator A5011313043 @default.
• W2103089294 creator A5011331570 @default.
• W2103089294 creator A5040741799 @default.
• W2103089294 creator A5058329121 @default.
• W2103089294 creator A5064896600 @default.
• W2103089294 creator A5070605719 @default.
• W2103089294 creator A5070933572 @default.
• W2103089294 creator A5074765508 @default.
• W2103089294 creator A5075004472 @default.
• W2103089294 creator A5085057753 @default.
• W2103089294 creator A5089737672 @default.
• W2103089294 date "2003-04-03" @default.
• W2103089294 modified "2023-10-18" @default.
• W2103089294 title "Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration" @default.
• W2103089294 cites W1539392991 @default.
• W2103089294 cites W1560497272 @default.
• W2103089294 cites W1606950487 @default.
• W2103089294 cites W1629086159 @default.
• W2103089294 cites W1805673099 @default.
• W2103089294 cites W1938199221 @default.
• W2103089294 cites W1965007784 @default.
• W2103089294 cites W1965339829 @default.
• W2103089294 cites W1975023188 @default.
• W2103089294 cites W1975331070 @default.
• W2103089294 cites W1980681889 @default.
• W2103089294 cites W2005700669 @default.
• W2103089294 cites W2010395737 @default.
• W2103089294 cites W2016760563 @default.
• W2103089294 cites W2018716226 @default.
• W2103089294 cites W2025325421 @default.
• W2103089294 cites W2026624933 @default.
• W2103089294 cites W2026709325 @default.
• W2103089294 cites W2041355017 @default.
• W2103089294 cites W2044293800 @default.
• W2103089294 cites W2046454316 @default.
• W2103089294 cites W2049656865 @default.
• W2103089294 cites W2066961374 @default.
• W2103089294 cites W2068210940 @default.
• W2103089294 cites W2068477037 @default.
• W2103089294 cites W2083748640 @default.
• W2103089294 cites W2088376899 @default.
• W2103089294 cites W2090409342 @default.
• W2103089294 cites W2096428903 @default.
• W2103089294 cites W2097293665 @default.
• W2103089294 cites W2101736298 @default.
• W2103089294 cites W2105382539 @default.
• W2103089294 cites W2114471594 @default.
• W2103089294 cites W2117909173 @default.
• W2103089294 cites W2124306144 @default.
• W2103089294 cites W2156675756 @default.
• W2103089294 cites W2163110760 @default.
• W2103089294 cites W2166052593 @default.
• W2103089294 doi "https://doi.org/10.1124/jpet.103.049700" @default.
• W2103089294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12676885" @default.
• W2103089294 hasPublicationYear "2003" @default.
• W2103089294 type Work @default.
• W2103089294 sameAs 2103089294 @default.
• W2103089294 citedByCount "61" @default.
• W2103089294 countsByYear W21030892942012 @default.
• W2103089294 countsByYear W21030892942013 @default.
• W2103089294 countsByYear W21030892942014 @default.
• W2103089294 countsByYear W21030892942015 @default.
• W2103089294 countsByYear W21030892942018 @default.
• W2103089294 countsByYear W21030892942019 @default.
• W2103089294 countsByYear W21030892942021 @default.
• W2103089294 countsByYear W21030892942022 @default.
• W2103089294 crossrefType "journal-article" @default.
• W2103089294 hasAuthorship W2103089294A5005928205 @default.
• W2103089294 hasAuthorship W2103089294A5006974397 @default.
• W2103089294 hasAuthorship W2103089294A5009703315 @default.
• W2103089294 hasAuthorship W2103089294A5011313043 @default.
• W2103089294 hasAuthorship W2103089294A5011331570 @default.
• W2103089294 hasAuthorship W2103089294A5040741799 @default.
• W2103089294 hasAuthorship W2103089294A5058329121 @default.
• W2103089294 hasAuthorship W2103089294A5064896600 @default.
• W2103089294 hasAuthorship W2103089294A5070605719 @default.
• W2103089294 hasAuthorship W2103089294A5070933572 @default.
• W2103089294 hasAuthorship W2103089294A5074765508 @default.
• W2103089294 hasAuthorship W2103089294A5075004472 @default.
• W2103089294 hasAuthorship W2103089294A5085057753 @default.
• W2103089294 hasAuthorship W2103089294A5089737672 @default.
• W2103089294 hasConcept C126322002 @default.
• W2103089294 hasConcept C142724271 @default.
• W2103089294 hasConcept C181199279 @default.
• W2103089294 hasConcept C185592680 @default.
• W2103089294 hasConcept C25498285 @default.
• W2103089294 hasConcept C2776706248 @default.
• W2103089294 hasConcept C2776925932 @default.
• W2103089294 hasConcept C2777896816 @default.
• W2103089294 hasConcept C2779134260 @default.
• W2103089294 hasConcept C2779689624 @default.
• W2103089294 hasConcept C2781000538 @default.
• W2103089294 hasConcept C2781156865 @default.

• next